Roche receives FDA clearance for strep A test on cobas Liat System
Posted: 14 November 2014 |
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Strep A test for the detection of group A streptococcus bacterial (Strep A) DNA in throat swab specimens. The cobas Strep A test runs on the cobas Liat System, a molecular point of care diagnostic system, which will be launched later this year. With a time to result of just 15 minutes, the cobas Strep A test achieves outstanding sensitivity aiding healthcare professionals to make immediate, informed treatment decisions in a variety of testing locations.
Strep A is the cause of strep throat, as well as certain skin infections, scarlet fever, and toxic shock syndrome. About 37% of sore throats among children1 and 5-15% in adults2 are caused by Strep A and infection is most common between the ages of 5 and 153.
“The cobas Strep A test is easy to use and provides accurate results to support a treatment decision in just 15 minutes, much faster than current technologies,” said Roland Diggelmann, COO of Roche Diagnostics. “It also provides a significant improvement over conventional methods such as culture testing, where patients can wait up to 2 days to receive their result, or rapid antigen testing where confirmation with culture is needed due to significantly lower sensitivity.”
The new cobas Strep A test adds to the growing portfolio of assays designed for use with the cobas Liat System, enabling healthcare professionals to perform molecular PCR testing in a variety of settings with speed, accuracy, reliability and minimal training. The analyzer and two initial assays (cobas Influenza A/B and cobas Strep A) are both CE Marked and FDA cleared. Roche expects to begin sales of the system and assays later this year.
*The cobas Liat System is not currently CLIA Waived in the United States
References
- Shaikh N, Leonard E, Martin JM (September 2010). “Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis”. Pediatrics 126 (3): e557–64. doi:10.1542/peds.2009-2648
- Shulman, ST; Bisno, AL; Clegg, HW; Gerber, MA; Kaplan, EL; Lee, G; Martin, JM; Van Beneden, C (Sep 9, 2012). “Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America.”. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 55 (10): e86–102. doi:10.1093/cid/cis629.
- http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001663